KZR
Kezar Life Sciences, Inc.Company Information
- Company Name
- Kezar Life Sciences, Inc.
- CIK
- CIK0001645666
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KZR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KZR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-07-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 7,513
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 4,275,448
- Shares outstanding
- 7,343,909
- Ownership
- 58.22%
Earnings Market Reaction
- Filing date
- 2026-05-11
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 66 | 72 | 39 | 34 | 37 | 42 | 35 | 28 | 33 | 35 | 26 | 28 | ||||||
| Marketable Securities Current | - | 0 | 51 | 66 | 77 | 90 | 114 | 136 | 147 | 166 | 192 | 208 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | 7 | - | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | 4 | 6 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 3 | 4 | 4 | 6 | 5 | 8 | 3 | 6 | 6 | - | - | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | 0 | 1 | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Assets Current | 68 | 76 | 95 | 105 | 120 | 137 | 156 | 168 | 186 | 207 | 231 | 244 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | ||||||
| Operating Lease Right Of Use Asset | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 4 | 5 | 8 | 9 | ||||||
| Other Assets Noncurrent | - | 0 | 0 | 1 | 1 | 2 | 2 | 7 | 6 | 6 | 6 | 7 | ||||||
| Assets | 68 | 77 | 98 | 109 | 125 | 145 | 164 | 180 | 199 | 221 | 249 | 263 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 1 | 1 | 1 | 2 | 4 | 3 | 2 | 5 | 8 | 3 | 2 | ||||||
| Accrued Liabilities Current | - | 4 | - | - | - | 8 | - | - | - | 6 | - | - | ||||||
| Operating Lease Liability Current | 1 | 2 | 3 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | 4 | 3 | 1 | - | - | - | ||||||
| Debt Current | - | 0 | 5 | 5 | 5 | 5 | - | - | - | 0 | - | - | ||||||
| Liabilities Current | 3 | 7 | 13 | 14 | 17 | 20 | 20 | 17 | 16 | 18 | 17 | 14 | ||||||
| Liabilities | 3 | 7 | 15 | 17 | 22 | 28 | 30 | 29 | 30 | 34 | 33 | 31 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 7 | ||||||
| Long Term Debt Noncurrent | - | 0 | 1 | 3 | 4 | 5 | 6 | 8 | 9 | 10 | 10 | 10 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 562 | 561 | 559 | 557 | 554 | 552 | 548 | 545 | 542 | 538 | 535 | 528 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -496 | -491 | -476 | -465 | -451 | -434 | -414 | -394 | -372 | -351 | -319 | -295 | ||||||
| Stockholders Equity | 65 | 70 | 83 | 92 | 103 | 117 | 134 | 151 | 169 | 188 | 216 | 232 | ||||||
| Liabilities And Stockholders Equity | 68 | 77 | 98 | 109 | 125 | 145 | 164 | 180 | 199 | 221 | 249 | 263 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Shares Outstanding | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKezar Life Sciences, Inc. (KZR) — SEC Financial Statements & Analysis
Kezar Life Sciences, Inc. (KZR) is a pharmaceutical preparations company, incorporated in DE. Kezar Life Sciences, Inc. trades on Nasdaq as: KZR. Kezar Life Sciences, Inc. (KZR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-11. Based on that filing, On profitability, Kezar Life Sciences, Inc. posts an operating margin of -1531.57%, a net margin of -1408.11%, a Return on Equity (ROE) of -53.75%, a Return on Assets (ROA) of -46.81%, and a Return on Invested Capital (ROIC) of -81.81%. Per share, it reports EPS of $-6.16, diluted EPS of $-6.16, free cash flow per share of $-5.72, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -42.48% year-over-year, and EPS growth of -42.78% year-over-year. On the balance sheet, it maintains a current ratio of 24.46x, a quick ratio of 23.98x, working capital of $64.80M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -161.73x, free cash flow of $-42.03M (TTM), and net debt of $-66.23M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-6.16
- ROE TTM
- -53.75%
- ROA TTM
- -46.81%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-42.03M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kezar Life Sciences, Inc. in?
Kezar Life Sciences, Inc. (KZR) operates in the Pharmaceutical Preparations industry.
What exchange does KZR trade on?
Kezar Life Sciences, Inc. (KZR) trades on the Nasdaq.
Where is Kezar Life Sciences, Inc. incorporated?
Kezar Life Sciences, Inc. is incorporated in DE.
When was Kezar Life Sciences, Inc. (KZR)'s most recent SEC filing?
Kezar Life Sciences, Inc. (KZR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-11.
What is KZR's EPS (earnings per share)?
Kezar Life Sciences, Inc. (KZR)'s trailing twelve month EPS is $-6.16 as of 2026-03-31.
What is KZR's ROE (return on equity)?
Kezar Life Sciences, Inc. (KZR)'s trailing twelve month Return on Equity (ROE) is -53.75% as of 2026-03-31.
What is KZR's ROA (return on assets)?
Kezar Life Sciences, Inc. (KZR)'s trailing twelve month Return on Assets (ROA) is -46.81% as of 2026-03-31.
What is KZR's ROIC (return on invested capital)?
Kezar Life Sciences, Inc. (KZR)'s trailing twelve month Return on Invested Capital (ROIC) is -81.81% as of 2025-09-30.